Kyverna Therapeutics is progressing its drug mivocabtagene autoleucel for autoimmune diseases, targeting approval for stiff person syndrome. Updated trial data show all 26 patients stopped chronic immunotherapies at 16 weeks, with 81% reporting improved mobility, boosting regulatory confidence. The company is submitting a rolling Biologics License Application, aiming for completion by late 2026 and potential approval by mid-2027, with key phase 2/3 data in myasthenia gravis expected soon. Kyverna's cash runway extends into 2028, but a significant equity raise may be needed in 2027 due to a narrow margin before commercialization and a limited initial market size.
SK Hynix has approved a $38 billion investment to build new memory fabrication plants. However, these new fabs are not expected to produce any chips before December 2028, indicating a long-term expansion plan. This move highlights SK Hynix's commitme...
Over the past decade, an investment of $10,000 in AMD grew to more than $700,000, significantly outperforming the S&P 500, which turned the same amount into about $42,000. This highlights AMD's exceptional growth and strong market performance compare...
Changpeng Zhao (CZ), former Binance CEO, is donating all BNB and BinanceLife tokens from a public wallet to Giggle Academy, a nonprofit offering free education. After the transfer, CZ will abandon the wallet, turning it into a burn address to prevent...
Kaito's price has fallen about 11% in the past day, continuing a week-long decline driven by whale selling. This trend is linked to an upcoming token unlock on August 20, releasing 32.6 million KAITO tokens, which may increase selling pressure amid b...
Bitcoin is trading around $63,038, about 19% below its May peak near $77,500, prompting some skepticism about its future value. Citi, Standard Chartered, and TD Cowen have all lowered their 2026 Bitcoin price targets, reflecting softer demand and reg...
